How Is Immunotherapy Improving?

Read Transcript

Right now, we have effective immuno therapies for patients with melanoma and kidney cancer that is [XX] to approved. We have eporuma mab approved only for melanoma and just as of last week anti PD1 just for melanoma. My guess is the response for renonal cancer will probably be in the 15% range, 20% range.

But except in rare instances is best we can tell now, most of the common epaphilio cancer that kill 80% of every one of the almost 600,000 of Americans that die of cancer each year appear not to be touched by the existing immuno therapies, which is why we are so excited about this new approach.

Now for the common epithilial cancers, these are cancers that start in the linings of ducts within organs like pancreas, esophagus, the ovary, the prostate, the stomach. We don't have any other therapies for those cancers. But by developing a technique to target the individual mutation in those cancers, we may now be able to develop immunotherapies, this is highly experimental aganist the common cancers.

See most people don't realize how few cancers we can actually cure. With any therapy, with any chemotherapy or systemic treatment. I mean we have at 60 years ago the development of methotrexate, that could treat women with metastatic cardio carcinoma. Very rare cancer that starts in the placenta.

We have maybe 40 years of 30 to 40 years ago drugs platinum [xx] that could cure patients with germ cell tumors, like [XX] Armstrong had, testicular cancers. Except for those two, we have no systemic treatment of any kinds that will cure any patient with any common cancer, once it's metastasized.

With the exception of immuno therapy and we're looking into familiar name, but when you develop [xx] breast cancer, colon cancer, prostate ovary, stomach, you name it. We can cause those cancers to regress temporarily, but we can't cure any of those patients with any available systemic treatments.

And it's one of my hopes, that immunotherapy now can bridge that gap, and more effectively treat patients with these common cancers. If you look at the blockbuster drugs that exist, like, [xx] in the fields of blood supply. When you add that to chemotherapy, it prolong survival by four and a half months.

A lot of that proved by FDA for patients with pancreatic cancer improve survival in metastic pancreotic cancer by twelve days and approved by the FDA. Of course about before out of money tens and thousands of dollars. But again, we're taking about shrinkages that are temporary. The only cancers we can cure now is system treatment, kidney cancer with vio 2 and this other rare cancers [XX] and [XX].

So we are in desperate state, we need curative treatments for patients with [XX]. And as we look at this health care crisis that we're in right now, the based way to save healthcare dollars is to cure patients. So they don't move from one ineffective treatment to the next ineffective treatment each one is being quite expensive.